LXRX vs ARDX vs INVA vs PTGX vs FOLD

For growth investors, Lexicon Pharmaceuticals, Inc.

(LXRX) is the stronger pick with 60. 2% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Ardelyx, Inc. (ARDX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Innoviva, Inc.

is actually cheaper at 11. 9x.

Over the past 5 years, Ardelyx, Inc.

(ARDX) delivered a total return of +313. 0%, compared to -63. 3% for Lexicon Pharmaceuticals, Inc. (LXRX). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus LXRX's -86. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Lexicon Pharmaceuticals, Inc. 's 1. 46β — meaning LXRX is approximately 1054% more volatile than INVA relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lexicon Pharmaceuticals, Inc.

(LXRX) is pulling ahead at 60. 2% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, LXRX leads at 610. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — LXRX leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 9x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 28. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LXRX: 257. 1% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Both have compounded well over 10 years (PTGX: +744. 9%, LXRX: -86. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LXRX is a small-cap high-growth stock; ARDX is a small-cap high-growth stock; INVA is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.